Here’s what you need to know:
1. Two-thirds of patients treated with Kanuma for 52 weeks experienced reduced liver fibrosis.
2. Half of patients treated with Kanuma for 52 weeks experienced at least a two-stage reduction in liver fibrosis.
3. Kanuma-treated patients also experienced improvements in alanine aminotransferase, LDL cholesterol and liver fat content.
More articles on gastroenterology and endoscopy:
Takeda Pharmaceutical, New York Academy of Sciences establish $200k research prize: 3 notes
Clinical Genomics’ circulating tumor DNA blood test proves effective for CRC recurrence detection: 3 notes
AGA, NACCME develop 3 regional educational programs about IBD: 3 notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.